Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies

This publication has 11 references indexed in Scilit:

• Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy
  British Journal of Haematology, 2015
• Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients
  Bone Marrow Transplantation, 2015
• Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital
  Supportive Care in Cancer, 2014
• Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
  Haematologica, 2014
• Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection
  Blood Reviews, 2014
• Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis
  Leukemia & Lymphoma, 2013
• Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients
  Annals of Hematology, 2013
• Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients
  Annals of Hematology, 2013
• Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
  Journal of Clinical Oncology, 2008
• One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation
  Blood, 2007